Navigation Links
First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder

Treatment Benefits Were Maintained for at Least 24 Weeks, According to Report Published in The Journal of Urology

LONDON, May 15, 2007 /PRNewswire/ -- Researchers from Guy's Hospital and King's College London School of Medicine have announced the results from the first randomized, double-blind, placebo-controlled study evaluating botulinum toxin type A (BTX-A, BOTOX(R)) as a treatment for idiopathic detrusor overactivity (IDO) in patients with symptoms of overactive bladder (OAB). The trial results which are published in the June 2007 issue of The Journal of Urology show that BTX-A is safe and effective for this use and that the beneficial effects -- including improved quality of life -- persist for at least 24 weeks.

"The findings of this study are important because there is a need for new treatments for OAB patients who have unsatisfactory responses to therapies which are currently available and who do not want to consider invasive surgery," said Mr. Arun Sahai, who was a principal investigator of the study during his time as a research fellow at Guy's Hospital, London. "This study demonstrated that botulinum toxin type A may be a promising treatment option for patients with OAB symptoms."

OAB is characterized by feelings of urgency to urinate, with or without incontinence, and is usually accompanied by increased urination frequency and nocturia (excessive urination at night). A large proportion of OAB patients have what is referred to as idiopathic detrusor overactivity or IDO -- excessive activity of the muscles that contract the bladder, due to an unknown cause -- and are treated with drugs called anticholinergics (e.g., tolterodine). However, many OAB patients discontinue medication due to insufficient relief of symptoms or intolerable side effects that can include dry mouth, dry eyes, constipation and headache.

"This study showed that this treatment had real benefits for patients for
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/4/2015)... N.J. and LOS ANGELES ... Diagnostics (NYSE: DGX ), the world,s leading ... it has completed the previously announced acquisition of ... As a result of the transaction, ... extensive range of innovative services and network of ...
(Date:8/4/2015)... 2015  Sutro Biopharma today announced that it ... vice president of alliance and project management. Dr. ... management of Sutro,s collaborative partnerships and the development ... bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... years of experience in the biopharmaceutical sector with ...
(Date:8/4/2015)... 4, 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... summarizing data from studies in Europe ... Hepatic CHEMOSAT ® Delivery System (CHEMOSAT) will be presented ... congress, which will be held in Marseille, ...
Breaking Medicine Technology:Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4
... Inc., a neurology-focused specialty pharmaceutical company, announced today that ... of CAMBIA™ (diclofenac potassium for oral solution) will be ... Neurology Conference (CONy) in Barcelona, Spain. The ... entitled, "Rapid and Sustained Improvement in Migraine Symptoms with ...
... joint guideline by the American Society of Hematology (ASH) ... physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), ... to produce more red blood cells, to treat cancer ... ESAs are associated with shorter survival and increased risk ...
Cached Medicine Technology:New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 2New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 3New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 4New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 2New Guideline from ASH and ASCO Recommends Caution Regarding ESA Use in Cancer Patients 3
(Date:8/4/2015)... (PRWEB) , ... August 05, 2015 , ... The ... Pain and Obesity ”. , As corresponding author Professor Akiko Okifuji says “Both obesity ... often, although it is not to say that one causes the other. Rather, there ...
(Date:8/4/2015)... ... 2015 , ... Exsurco Medical, Inc. is proud ... as an Affiliate Member. Exsurco Medical finds this an exciting opportunity to ... lives by promoting the safety, quality and availability of donated tissue for transplantation, ...
(Date:8/4/2015)... ... 2015 , ... The United Nations Foundation today announced a ... for a select group of U.S.-based journalists during the week of November 9, ... International Conference on Family Planning in Bali. , In close coordination with ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... formula. Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that ... a capsule for those applications which have more of a semi-solid composition. ...
(Date:8/4/2015)... ... 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM headlamp ... hats that have a flip-up face shield. The sleek contours of the new ... to remove their headlamp when raising or lowering their face shield or visor. The ...
Breaking Medicine News(10 mins):Health News:The Association between Chronic Pain and Obesity published by Dove Medical Press 2Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3
... in Wonderland was well advised to stay asleep especially as ... in the tea-time conversation. Dormice in Europe spend about eight ... extended period, with almost all of them surviving the winter. ... Austria, the Czech Republic, England, Germany and Italy. Karin Lebl ...
... close attention to how the United Kingdom carries out plans ... beyond clinical and cost effectiveness, according to researchers at the ... to appear in the April 7 issue of the ... discuss a new, "value-based pricing" policy proposed by the British ...
... -- Having a good laugh on April Fool,s Day or ... benefits your blood vessels, an expert says. "Laughter increases ... stress is especially beneficial for persons who have hypertension [high ... Vascular Surgery news release. April is National Stress Awareness ...
... a unique system to perform in vivo RNAi ... that regulate hepatocyte proliferation during chronic liver damage.1 ... stable knockdown of the candidate gene by different ... mouse hepatocytes and also increase the regenerative capacity ...
... 1 issue of the journal SLEEP demonstrates that an ... sleep disturbances, as well as providing positive, indirect benefits ... that the Internet can give parents widespread access to ... children. Results show that there were significant improvements ...
... Researchers have found that it may not be necessary to ... analyzing non-tumor tissue may be an effective option, according to ... of the American Association for Cancer Research. "A ... detect the presence of tumor," said lead researcher Dan Mercola, ...
Cached Medicine News:Health News:Sleeping through danger: the dormouse approach to survival 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 2Health News:Internet program reduces infant and toddler sleep problems, helps moms sleep better too 3Health News:New tool allows for an alternate method of prostate cancer diagnosis 2
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Medicine Products: